***NATEA SIG Biotech's***

***NOVEMBER 2004 BIOTECH***

***PRE-CONFERENCE WORKSHOP***

***"A US-TAIWAN BIOTECH FORUM"***

*presented and sponsored by:*

# *NATEA-SILICON VALLEY:*

**THE NORTH AMERICA TAIWANESE ENGINEERS' ASSOCIATION'S**

**SIG BIOTECH**

**DON'T MISS OUT ON THIS VALUABLE OPPORTUNITY FOR NETWORKING IN BIOTECHNOLOGY, AND TO ATTEND CUTTING-EDGE BUSINESS PRESENTATIONS FROM BIOTECHNOLOGY EXECUTIVE LEADERS AND RESEARCHERS**

**FREE!**

***PRESENTATIONS:***

*(1)"The Outlook of Future Perspectives in Drug Delivery"*

*(2)"New Platform Technologies in Drug Design"*

*and*

*(3) "A Cross-Pacific Business Model from the Taiwan Liposome Company"*

| | |
|---|---|
| ***DATE:*** | **Friday, November 5, 2004** |
| ***TIME:*** | **6:30PM to 9:30PM** |
| ***LOCATION:*** | **The Los Altos Library**<br>**13 S. San Antonio Rd., Los Altos, California 94022** |

***REGISTRATION FEE:*** **FREE TO EVERYONE**

***PROGRAM SCHEDULE:***

1. **6:30 –7:00** *NETWORKING*
2. **7:00-7:30** "THE OUTLOOK OF FUTURE PERSPECTIVES IN DRUG DELIVERY"

*SPEAKER:* Eric Sheu, Ph.D. Research Fellow, Durect Corp.

"Review of drug delivery, discussion of strategies towards developing suitable formulation, outlook of perspectives, and more."

**(Please note that Mr. Sheu needs to leave at 7:30 sharp, so please be on time so as to not miss this talk.)**

3. **7:30-8:15** "MULTI-ACTIVITY DRUG DESIGN"

*SPEAKER:* Jay Wu, Ph.D. President & CEO, VM Discovery

"VM Discovery, Inc.'s ("VMD") proprietary platform technology ("VM Optimizer™")- to identify patentable and druggable small molecule drug leads with balanced biological activity (potency) and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties."

4. **8:15-9:00** "CROSS-PACIFIC BUSINESS MODEL FOR DRUG DELIVERY~ TAIWAN LIPOSOME COMPANY"

*SPEAKER:* George Yeh, MBA, General Manager of the Taiwan Liposome Company

***FOR QUESTIONS OR RSVP,***

**PLEASE CONTACT NATEA SIG BIOTECHNOLOGY'S CHAIPERSON, DR. SHU-LING CHENG, PHD at EMAIL: slcheng1@yahoo.com**

***PROGRAM and SPEAKER DESCRIPTIONS:***

## "THE OUTLOOK FOR FUTURE PERSPECTIVES IN DRUG DELIVERY"

***ABSTRACT:*** Drug delivery systems are vital for pharmaceutical industry in release profile tailoring (fast, controlled and sustained releases), product life extension, site-specific targeting, toxicity reduction, taste masking, and others. There are potent drugs that are available for quite some time but without approval for commercial practice. Many of them are due to lack of a proper delivery system. In this presentation, a brief review of drug delivery technologies will be given, followed by a discussion on the strategies toward developing suitable formulations for given product concepts. Examples used for demonstration include small molecules, peptides, proteins and DNAs. Finally, an outlook of the future perspectives in drug delivery will be proposed.

***SPEAKER BIOGRAPHY:*** **ERIC Y. SHEU**

- MIT, Ph.D., Applied Radiation Physics (Micelle and microemulsion systems)

- Durect Corp – Research Fellow, Small molecules sustained release, paste/emulsion, semi-solid formulations.
- Genteric Inc. – DNA, peptide, protein, small molecule controlled/sustained release liquid formulations; microencapsultion and nanoparticles
- Guidant – Drug eluting stent formulations
- Zeneca – Controlled/sustained release small molecule tablets, emulsions, semi-solid, microencapsulation
- Exxon/Texaco – Surfactant solution/emulsion formulations and characterizations

## "MULTI-ACTIVITY DRUG DESIGN"

***ABSTRACT:*** The success of genomics has sharply expanded the pool of therapeutic targets. However, the output of new drugs or NCEs (New Chemical Entities) has not been increased so far, while the R&D costs for pharmaceutical companies have been actually going up. VM Discovery, Inc. ("VMD") has developed proprietary platform technology ("VM Optimizer™"), based on integrated parallel multi-property drug design, virtual screening and optimization to identify patentable and druggable small molecule drug leads with balanced biological activity (potency) and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties. VMD's technology makes it possible for its partners at pharmaceutical and biotechnology companies to produce **superior** medicines in a **shorter** time with **fewer** resources. Products developed using VM Optimizer™, are novel in structures and are more potent, cost effective and safer with fewer side effects than the prior-generation counterparts. VMD has been developing a selected portfolio of novel drug lead families and scaffolds for validated disease targets (in anti-cancer, diabetes and cardiovascular diseases). VMD currently has drug discovery collaborations with pharmaceutical and biotech companies in US and Asia. With a few corporate clients (*e.g.* AstraZeneca, Neurocrine, TargeGen and ChemGenex, *etc.*), VMD has achieved "proof of principle" with its technology in finding and blindly validating several its in-vitro and in-vivo animal computational models by identifying novel, potent molecules with balanced ADMET properties (anti-cancer and cardiovascular diseases). VMD's unique approaches will significantly reduce the time to market and the failure rate of drug development, as well as increase the output of NCEs, thus showcase the change of drug discovery paradigm in the post-genomic era. This business model allows both **scalability** and **profitability** in a shorter time.

***SPEAKER BIOGRAPHY:*** **DR. JAY WU**

Dr. Jay Wu is President, CEO and Founder of VM Discovery, Inc. ("VMD"), a venture capital backed drug discovery company, located in Silicon Valley, California. VMD is specializing in parallel multi-property drug design and discovery of novel drug candidates by its proprietary computational technology, with more than 10 internal projects and more than 15 predictive in-silico ADMET models. Dr. Wu has spent over 17 years in developing computational algorithms for simulation and molecular modeling in chemical and biological systems and drug discovery. Before founding VM Discovery, he was founding Director of Computational Modeling at Camitro (acquired by ArQule), responsible for R&D of drug design and computational predictive models for the pharmacokinetics/ADME (Absorption, Distribution, Metabolism and Excretion)

and other pharmacokinetics from molecular structures. He developed and validated more than half of the Camitro's products at the time of $100M Camitro's acquisition by ArQule.

Dr. Wu is also one of the principal developers of some early commercial software programs used in drug discovery and development. He previously held positions, as Director, Manager of Molecular Modeling at NaviCyte, acquired by Trega Biosciences, and then subsequently acquired by Lion Biosciences, and at Simulations Plus, Inc. and at UC-Davis. He earned his Ph.D. in Chemistry from the University of Konstanz, Germany. His doctoral work focused on computational simulation, theoretical understanding, and experiments of the magnetic field effects on fast reaction kinetics of organic radicals in biomimic systems.

**FOR MORE INFORMATION ABOUT NATEA:**
**WEBSITE: HTTP://WWW.NATEA.ORG**